Versant Venture Management, LLC
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 7, 2025), Versant Venture Management, LLC reported 7 stock positions worth $60.2 million. Its top holding was Monte Rosa Therapeutics (GLUE) at 43.6% of the portfolio, followed by Crispr Therapeutics (CRSP, 28.2%) and Contineum Therapeutics Class A (CTNM, 10.6%). Compared with Q4 2024, it opened 1 new position and sold out of 1. The biggest buy was a new position in Tempest Therapeutics (TPST) and the biggest sale an exit from Tempest Therapeutics (TPST).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001560009
- Portfolio Value
- $60.2M (Q1 2025)
- SEC Filing
- 0000950123-25-004223 ↗ filed May 7, 2025
Holdings Value
Holdings 7 stocks · $60.2M
| GLUE Monte Rosa Therapeutics Inc. | 43.56% | 5,652,922 | $26.2M | No change |
| CRSP Crispr Therapeutics AG | 28.18% | 498,558 | $17.0M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 10.64% | 918,163 | $6.4M | No change |
| SKYE Skye Bioscience Inc. | 5.30% | 2,007,704 | $3.2M | No change |
| RPTX Repare Therapeutics Inc. | 4.33% | 2,646,657 | $2.6M | No change |
| TPST Tempest Therapeutics Inc. | 4.30% | 3,507,055 | $2.6M | New |
| ADVM Adverum Biotechnologies Inc. | 3.68% | 506,821 | $2.2M | No change |
Portfolio Sells Q4 2024 → Q1 2025
| TPST Tempest Therapeutics Inc. | Sold out | 0.00% | −3.37 |
Portfolio Buys Q4 2024 → Q1 2025
| TPST Tempest Therapeutics Inc. | New | 4.30% | +4.30 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 8 | $162.6M | GLUE, IPSC, JBIO, LENZ, CTNM |
| Q1 2026 | 8 | $141.4M | GLUE, IPSC, LENZ, JBIO, CTNM |
| Q4 2025 | 7 | $151.1M | GLUE, LENZ, JBIO, CRSP, CTNM |
| Q3 2025 | 9 | $212.5M | LENZ, GLUE, JBIO, CRSP, SKYE |
| Q2 2025 | 8 | $82.1M | GLUE, CRSP, JBIO, SKYE, RPTX |
| Q1 2025 | 7 | $60.2M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q4 2024 | 7 | $86.7M | GLUE, CRSP, CTNM, SKYE, RPTX |
| Q3 2024 | 6 | $63.6M | CRSP, CTNM, RPTX, SKYE, ADVM |
| Q2 2024 | 8 | $77.3M | CRSP, CTNM, SKYE, RPTX, ADVM |
| Q1 2024 | 7 | $103.1M | CRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM |